<unk> , sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity. It contains<unk> , an opioid antagonist, and<unk> , an aminoketone antidepressant. It is taken by mouth. Both medications have individually shown some evidence of effectiveness in weight loss, and the combination has been shown to have some synergistic effects on weight. In September 2014, a sustained release formulation of the drug was approved for marketing in the United States under the brand name Contrave. The combination was subsequently approved in the European Union in the spring of 2015, where it is sold under the name Mysimba. It was approved in Canada under the Contrave brand name in 2018.
Naltrexone/bupropion
Amitriptyline/chlordiazepoxide
Olanzapine/fluoxetine
Aripiprazole/sertraline
Buprenorphine/naltrexone
Low-dose naltrexone
Brief psychotherapy
MDMA-assisted psychotherapy